Granted Patent
B2
US 12,324,860 · App. 18/441,673 · Granted Jun 10, 2025
Methods of treating central nervous system disorders via administration of nanoparticles of an mTOR inhibitor and an albumin
Assignee:
Abraxis BioScience, LLC
View Patent ↗
Loading inventors, assignments & file history…
Abstract
The present application provides methods of treating a CNS disorder (such as glioblastoma and epilepsy) in an individual, comprising systemically (e.g., intravenously or subcutaneously) administering to the individual an effective amount of a composition comprising nanoparticles comprising an mTOR inhibitor (such as a limus drug, such as sirolimus or a derivative thereof) and an albumin, optionally further comprising administering a second agent (such as an anti-VEGF antibody, a proteasome inhibitor, or an alkylating agent).
Claims (20)
1. A method of treating epilepsy in an individual, comprising systemically administering to the individual an effective amount of a composition comprising nanoparticles comprising albumin-bound sirolimus, wherein the ratio of albumin to sirolimus in the nanoparticles is from about 1:1 to about 9:1.
2. The method of claim 1 , wherein the nanoparticle composition is administered once every week, twice every three weeks, or three times every four weeks.
3. The method of claim 1 , wherein the average diameter of the nanoparticles in the nanoparticle composition is no greater than about 200 nm.
4. The method of claim 1 , wherein the nanoparticle composition is administered to the individual at a dose of about 0.1 mg/m 2 to 25 mg/m 2 .
5. The method of claim 1 , wherein the nanoparticle composition is administered to the individual at a dose of about 1 mg/m 2 to 10 mg/m 2 , and wherein the nanoparticle composition is administered once every week, twice every three weeks, or three times every four weeks.
6. The method of claim 1 , wherein the nanoparticle composition is administered for at least about one to six cycles, wherein each cycle consists of 21 days or 28 days.
7. The method of claim 1 , wherein the individual is a human.
8. The method of claim 1 , wherein the nanoparticle composition is parenterally administered into the individual.
9. The method of claim 8 , wherein the nanoparticle composition is intravenously administered into the individual.
10. The method of claim 8 , wherein the nanoparticle composition is subcutaneously administered into the individual.
11. The method of claim 1 , wherein the epilepsy is associated with cortical dysplasia.
12. The method of claim 11 , wherein the epilepsy is associated with focal cortical dysplasia.
13. The method of claim 1 , wherein the epilepsy is associated with a lesion imaged by magnetic resonance imaging (MRI), or associated with tuberous sclerosis complex (TSC).
14. The method of claim 1 , wherein the epilepsy is associated with infantile spasms.
15. The method of claim 14 , wherein the epilepsy is surgically refractory epilepsy.
16. The method of claim 1 , wherein the epilepsy is metabolic epilepsy, immune epilepsy, or idiopathic localization-related epilepsy with a genetic basis.
17. The method of claim 1 , wherein the individual is selected for treatment on the basis of having an mTOR-activation aberration.
18. The method of claim 17 , wherein the mTOR-activating aberration comprises an aberration at one or more genes selected from the group consisting of PTEN, TSC1, TSC2, AKT1, MTOR, PI3K, PIK3CA, PIK3CG, RHEB, TP53, NF1, NF2, FGFR4, and BAP1.
19. The method of claim 18 , wherein the mTOR-activating aberration comprises a somatic mutation or germline mutation in the one or more genes.
20. The method of claim 18 , wherein the mTOR-activating aberration comprises a loss of function mutation or deletion of the one or more genes.
Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Mar 7, 2024
From: DESAI, NEIL P.; HOU, SHIHE
To: ABRAXIS BIOSCIENCE, LLC
Reel/Frame 066677/0809 →
Continuity (5)
Continuation
PCTUS2019023037
· Mar 19, 2019
Provisional Application
62645634
· Mar 20, 2018
Provisional Application
62815346
· Mar 7, 2019
References Cited (399)
US 5362478A
· Desai
· 1994
[cited by applicant]
US 5439686A
· Desai
· 1995
[cited by applicant]
US 5498421A
· Grinstaff
· 1996
[cited by applicant]
US 5505932A
· Grinstaff
· 1996
[cited by applicant]
US 5508021A
· Grinstaff
· 1996
[cited by applicant]
US 5512268A
· Grinstaff
· 1996
[cited by applicant]
US 5560933A
· Soon-shiong
· 1996
[cited by applicant]
US 5635207A
· Grinstaff
· 1997
[cited by applicant]
US 5639473A
· Grinstaff
· 1997
[cited by applicant]
US 5650156A
· Grinstaff
· 1997
[cited by applicant]
US 5665382A
· Grinstaff
· 1997
[cited by applicant]
US 5665383A
· Grinstaff
· 1997
[cited by applicant]
US 5916596A
· Desai
· 1999
[cited by applicant]
US 5997904A
· Magdassi
· 1999
[cited by applicant]
US 6096331A
· Desai
· 2000
[cited by applicant]
US 6506405B1
· Desai
· 2003
[cited by applicant]
US 6528067B1
· Magdassi
· 2003
[cited by applicant]
US 6537579B1
· Desai
· 2003
[cited by applicant]
US 6565842B1
· Sojomihardjo
· 2003
[cited by applicant]
US 6652884B2
· Falciani
· 2003
[cited by applicant]
US 6749868B1
· Desai
· 2004
[cited by applicant]
US 6753006B1
· Desai
· 2004
[cited by applicant]
US 7758891B2
· Desai
· 2010
[cited by applicant]
US 7771751B2
· Desai
· 2010
[cited by applicant]
US 7780984B2
· Desai
· 2010
[cited by applicant]
US 7820788B2
· Desai
· 2010
[cited by applicant]
US 7923536B2
· Desai
· 2011
[cited by applicant]
US 7981445B2
· De
· 2011
[cited by applicant]
US 8034375B2
· Desai
· 2011
[cited by applicant]
US 8034765B2
· De
· 2011
[cited by applicant]
US 8137684B2
· Desai
· 2012
[cited by applicant]
US 8138229B2
· Desai
· 2012
[cited by applicant]
US 8257733B2
· Desai
· 2012
[cited by applicant]
US 8268348B2
· Desai
· 2012
[cited by applicant]
US 8314156B2
· Desai
· 2012
[cited by applicant]
US 8735394B2
· Desai
· 2014
[cited by applicant]
US 8846771B2
· Desai
· 2014
[cited by applicant]
US 8853260B2
· Desai
· 2014
[cited by applicant]
US 8911786B2
· Desai
· 2014
[cited by applicant]
US 8927019B2
· Desai
· 2015
[cited by applicant]
US 8999396B2
· Desai
· 2015
[cited by applicant]
US 9012518B2
· Desai
· 2015
[cited by applicant]
US 9012519B2
· Desai
· 2015
[cited by applicant]
US 9061014B2
· Seward
· 2015
[cited by applicant]
US 9101543B2
· Desai
· 2015
[cited by applicant]
US 9149455B2
· Desai
· 2015
[cited by applicant]
US 9308180B2
· De
· 2016
[cited by applicant]
US 9370494B2
· Yeo
· 2016
[cited by applicant]
US 9393318B2
· Desai
· 2016
[cited by applicant]
US 9399071B2
· Desai
· 2016
[cited by applicant]
US 9399072B2
· Desai
· 2016
[cited by applicant]
US 9446003B2
· Desai
· 2016
[cited by applicant]
US 9511046B2
· Desai
· 2016
[cited by applicant]
US 9561288B2
· Desai
· 2017
[cited by applicant]
US 9585960B2
· Foss
· 2017
[cited by applicant]
US 9597409B2
· Desai
· 2017
[cited by applicant]
US 9675578B2
· Desai
· 2017
[cited by applicant]
US 9724323B2
· Desai
· 2017
[cited by applicant]
US 9820949B2
· Desai
· 2017
[cited by applicant]
US 9855220B2
· Desai
· 2018
[cited by applicant]
US 9884013B2
· Seward
· 2018
[cited by applicant]
US 9962373B2
· Desai et al.
· 2018
[cited by applicant]
US 20030185894A1
· Zenoni
· 2003
[cited by applicant]
US 20030187062A1
· Zenoni
· 2003
[cited by applicant]
US 20030199425A1
· Desai
· 2003
[cited by applicant]
US 20050004002A1
· Desai
· 2005
[cited by applicant]
US 20070116761A1
· Desai
· 2007
[cited by applicant]
US 20070128290A1
· Desai
· 2007
[cited by applicant]
US 20080160095A1
· Desai
· 2008
[cited by applicant]
US 20080161382A1
· Desai
· 2008
[cited by applicant]
US 20080280987A1
· Desai
· 2008
[cited by applicant]
US 20090130163A1
· Desai
· 2009
[cited by applicant]
US 20090263483A1
· Desai
· 2009
[cited by applicant]
US 20100035800A1
· Desai
· 2010
[cited by applicant]
US 20100112077A1
· Desai
· 2010
[cited by applicant]
US 20100166869A1
· Desai
· 2010
[cited by applicant]
US 20100291584A1
· Tseng et al.
· 2010
[cited by applicant]
US 20100297243A1
· Desai
· 2010
[cited by applicant]
US 20110052708A1
· Soon-shiong
· 2011
[cited by applicant]
US 20110118342A1
· De
· 2011
[cited by applicant]
US 20110151012A1
· Desai
· 2011
[cited by applicant]
US 20110165256A1
· Desai
· 2011
[cited by applicant]
US 20110196026A1
· De
· 2011
[cited by applicant]
US 20120128732A1
· Trieu
· 2012
[cited by applicant]
US 20120189701A1
· Desai
· 2012
[cited by applicant]
US 20120231082A1
· Desai
· 2012
[cited by applicant]
US 20120283205A1
· Desai
· 2012
[cited by applicant]
US 20130005678A1
· Sandvold
· 2013
[cited by applicant]
US 20130045240A1
· Tao
· 2013
[cited by applicant]
US 20130071438A1
· Desai
· 2013
[cited by applicant]
US 20130195922A1
· Desai
· 2013
[cited by applicant]
US 20130195983A1
· Desai
· 2013
[cited by applicant]
US 20130195984A1
· Desai
· 2013
[cited by applicant]
US 20130266659A1
· Desai
· 2013
[cited by applicant]
US 20130280336A1
· Desai
· 2013
[cited by applicant]
US 20140017315A1
· Desai
· 2014
[cited by applicant]
US 20140017316A1
· Desai
· 2014
[cited by applicant]
US 20140017323A1
· Desai
· 2014
[cited by applicant]
US 20140023717A1
· Desai
· 2014
[cited by applicant]
US 20140056986A1
· Desai
· 2014
[cited by applicant]
US 20140072630A1
· Tao
· 2014
[cited by applicant]
US 20140072631A1
· Trieu
· 2014
[cited by applicant]
US 20140079787A1
· Yeo
· 2014
[cited by applicant]
US 20140080901A1
· Desai
· 2014
[cited by applicant]
US 20140155344A1
· Desai
· 2014
[cited by applicant]
US 20140170228A1
· Desai
· 2014
[cited by applicant]
US 20140186447A1
· Desai
· 2014
[cited by applicant]
US 20140199404A1
· Heise
· 2014
[cited by applicant]
US 20140199405A1
· Pierce
· 2014
[cited by applicant]
US 20140271871A1
· Desai
· 2014
[cited by applicant]
US 20140302157A1
· Desai
· 2014
[cited by applicant]
US 20150050356A1
· Desai
· 2015
[cited by applicant]
US 20150079177A1
· Desai
· 2015
[cited by applicant]
US 20150079181A1
· Desai
· 2015
[cited by applicant]
US 20150104521A1
· Desai
· 2015
[cited by applicant]
US 20150111960A1
· Desai
· 2015
[cited by applicant]
US 20150165047A1
· Desai
· 2015
[cited by applicant]
US 20150190519A1
· Desai
· 2015
[cited by applicant]
US 20150190556A1
· Desai
· 2015
[cited by applicant]
US 20160015817A1
· Benettaib
· 2016
[cited by applicant]
US 20160151325A1
· Desai
· 2016
[cited by applicant]
US 20160228401A1
· Desai
· 2016
[cited by applicant]
US 20160374952A1
· Yeo
· 2016
[cited by applicant]
US 20170007569A1
· De
· 2017
[cited by applicant]
US 20170014373A1
· Desai
· 2017
[cited by applicant]
US 20170105951A1
· Desai
· 2017
[cited by applicant]
US 20170172975A1
· Desai
· 2017
[cited by applicant]
US 20170181988A1
· Malhotra
· 2017
[cited by applicant]
US 20170202782A1
· Pierce
· 2017
[cited by applicant]
US 20170203012A1
· Desai
· 2017
[cited by applicant]
US 20170333384A1
· Desai
· 2017
[cited by applicant]
US 20180015181A1
· Desai
· 2018
[cited by applicant]
US 20180064679A1
· Pierce
· 2018
[cited by applicant]
US 20180133157A1
· Desai
· 2018
[cited by applicant]
US 20180153863A1
· Desai
· 2018
[cited by applicant]
US 20180169017A1
· Desai
· 2018
[cited by applicant]
US 20180177771A1
· Desai
· 2018
[cited by applicant]
US 20180256551A1
· Desai et al.
· 2018
[cited by applicant]
US 20180289620A1
· Desai et al.
· 2018
[cited by applicant]
US 20180374583A1
· Goldstein
· 2018
[cited by applicant]
US 20190022020A1
· Desai
· 2019
[cited by applicant]
US 20190147986A1
· Luo
· 2019
[cited by applicant]
US 20190167629A1
· Desai
· 2019
[cited by applicant]
US 20190175564A1
· Desai
· 2019
[cited by applicant]
US 20190183789A1
· Seward
· 2019
[cited by applicant]
US 20190184031A1
· Desai
· 2019
[cited by applicant]
US 20190192477A1
· Desai
· 2019
[cited by applicant]
US 20190247357A1
· Foss
· 2019
[cited by applicant]
US 20190307732A1
· Desai
· 2019
[cited by applicant]
US 20190343789A1
· Desai
· 2019
[cited by applicant]
US 20200040398A1
· Desai
· 2020
[cited by applicant]
US 20200129469A1
· Renschler
· 2020
[cited by applicant]
US 20200138793A1
· Desai
· 2020
[cited by applicant]
US 20200246275A1
· Pierce
· 2020
[cited by applicant]
US 20200316216A1
· Desai
· 2020
[cited by applicant]
US 20210085621A1
· Desai et al.
· 2021
[cited by applicant]
US 20210137848A1
· Desai et al.
· 2021
[cited by applicant]
US 20210315823A1
· Desai et al.
· 2021
[cited by applicant]
US 20210322335A1
· Desai et al.
· 2021
[cited by applicant]
US 20220054404A1
· Desai et al.
· 2022
[cited by applicant]
US 20230000844A1
· Desai et al.
· 2023
[cited by applicant]
US 20230080409A1
· Desai
· 2023
[cited by applicant]
US 20230190715A1
· Desai
· 2023
[cited by applicant]
US 20230263779A1
· Desai
· 2023
[cited by applicant]
US 20230293449A1
· Desai et al.
· 2023
[cited by applicant]
US 20240009323A1
· Desai
· 2024
[cited by applicant]
US 20240065984A1
· Desai
· 2024
[cited by applicant]
US 20240082224A1
· Desai
· 2024
[cited by applicant]
AU 2015271950A1
· 2016
[cited by applicant]
EP 0393457B1
· 1994
[cited by applicant]
EP 0363284B1
· 1997
[cited by applicant]
EP 0364344B1
· 1998
[cited by applicant]
JP 2013511549A
· 2013
[cited by applicant]
WO 198810266A1
· 1988
[cited by applicant]
WO 199113904A1
· 1991
[cited by applicant]
WO 199212140A1
· 1992
[cited by applicant]
WO 199418954A1
· 1994
[cited by applicant]
WO 199814174A1
· 1998
[cited by applicant]
WO 199814175A1
· 1998
[cited by applicant]
WO 199900113A1
· 1999
[cited by applicant]
WO 200064437A1
· 2000
[cited by applicant]
WO 200071079A2
· 2000
[cited by applicant]
WO 200113904A2
· 2001
[cited by applicant]
WO 200113904A3
· 2001
[cited by applicant]
WO 200189522A1
· 2001
[cited by applicant]
WO 2002087545A1
· 2002
[cited by applicant]
WO 2003096944A1
· 2003
[cited by applicant]
WO 2004004749A1
· 2004
[cited by applicant]
WO 2004052401A2
· 2004
[cited by applicant]
WO 2004052401A3
· 2005
[cited by applicant]
WO 2006089207A2
· 2006
[cited by applicant]
WO 2006089290A1
· 2006
[cited by applicant]
WO 2007027819A2
· 2007
[cited by applicant]
WO 2007027941A2
· 2007
[cited by applicant]
WO 2007027819A3
· 2007
[cited by applicant]
WO 2007027941A3
· 2007
[cited by applicant]
WO 2006089207A3
· 2007
[cited by applicant]
WO 200071079A3
· 2008
[cited by applicant]
WO 2008027055A1
· 2008
[cited by applicant]
WO 2008057562A1
· 2008
[cited by applicant]
WO 2008076373A1
· 2008
[cited by applicant]
WO 2008109163A1
· 2008
[cited by applicant]
WO 2008137148A2
· 2008
[cited by applicant]
WO 2008150532A1
· 2008
[cited by applicant]
WO 2008137148A3
· 2009
[cited by applicant]
WO 2009112022A2
· 2009
[cited by applicant]
WO 2009124119A2
· 2009
[cited by applicant]
WO 2009126175A1
· 2009
[cited by applicant]
WO 2009126401A1
· 2009
[cited by applicant]
WO 2009126938A1
· 2009
[cited by applicant]
WO 2010068925A1
· 2010
[cited by applicant]
WO 2010105172A1
· 2010
[cited by applicant]
WO 2010118365A1
· 2010
[cited by applicant]
WO 2010121000A1
· 2010
[cited by applicant]
WO 2010129622A1
· 2010
[cited by applicant]
WO 2011025838A1
· 2011
[cited by applicant]
WO 2011063309A1
· 2011
[cited by applicant]
WO 2011119988A1
· 2011
[cited by applicant]
WO 2011123393A1
· 2011
[cited by applicant]
WO 2011123395A1
· 2011
[cited by applicant]
WO 2011153009A1
· 2011
[cited by applicant]
WO 2011153010A1
· 2011
[cited by applicant]
WO 2011156119A1
· 2011
[cited by applicant]
WO 2012149451A1
· 2012
[cited by applicant]
WO 2013090634A1
· 2013
[cited by applicant]
WO 2014105644A1
· 2014
[cited by applicant]
WO 2014110345A1
· 2014
[cited by applicant]
WO 2014110408A1
· 2014
[cited by applicant]
WO 2014110443A1
· 2014
[cited by applicant]
WO 2014123612A1
· 2014
[cited by applicant]
WO 2014143613A1
· 2014
[cited by applicant]
WO 2014151853A1
· 2014
[cited by applicant]
WO 2014159171A1
· 2014
[cited by applicant]
WO 2015157120A1
· 2015
[cited by applicant]
WO 2016057712A1
· 2016
[cited by applicant]
WO 2016141365A1
· 2016
[cited by applicant]
WO 2017004249A1
· 2017
[cited by applicant]
WO 2017004266A1
· 2017
[cited by applicant]
WO 2017004267A1
· 2017
[cited by applicant]
WO WO2017004264A1
· 2017
[cited by examiner]
WO 2017201189A1
· 2017
[cited by applicant]
WO 2018064405A1
· 2018
[cited by applicant]
WO 2018067943A1
· 2018
[cited by applicant]
WO 2018071399A1
· 2018
[cited by applicant]
WO 2019126223A1
· 2019
[cited by applicant]
WO 2019183146A1
· 2019
[cited by applicant]
WO 2019226685A1
· 2019
[cited by applicant]
WO 2020191053A1
· 2020
[cited by applicant]
WO 2021086946A1
· 2021
[cited by applicant]
WO 2021096997A1
· 2021
[cited by applicant]
Citraro, R., et al., mTOR pathway inhibition as a new therapeutic strategy in epilepsy and epileptogenesis, Pharm. Res., 107 (2016) pp. 333-343. (Year: 2016).
[cited by examiner]
Adams, J. (May 2004). “The Proteasome: A Suitable Antineoplastic Target,” J. Nat. Rev. Cancer 4:349-360.
[cited by applicant]
Altmayer, P. et al. (1995). “Propofol Binding to Human Blood Proteins,” Arzneimittelforschung 45:1053-1056.
[cited by applicant]
Angliker, H. et al. (1987). “The Synthesis of Lysyifluoromethanes and Their Properties as Inhibitors of Trypsin, Plasmin and Cathepsin B,” Biochem. J. 241:871-875.
[cited by applicant]
Badesch, D. B. et al. (2010). “Pulmonary Arterial Hypertension: Baseline Characteristics From the REVEAL Registry,” Chest 137(2):376-387.
[cited by applicant]
Barry, W. T. et al. (2005, e-pub. Jan. 10, 2005). “Significance Analysis of Functional Categories in Gene Expression Studies: A Structured Permutation Approach,” Bioinformatics 21(9):1943-1949.
[cited by applicant]
Bussemaker, H. J. et al. (Sep. 27, 2007). “Dissecting Complex Transcriptional Responses Using Pathway-Level Scores Based on Prior Information,” BMC Bioinformatics 8(Suppl. 6): S6, 7 pages.
[cited by applicant]
Calatozzolo, C., et al. (2012, e-pub. Jul. 26, 2012). “Multidrug Resistance Proteins Expression in Glioma Patients with Epilepsy,” J. Neurooncol. 110:129-135.
[cited by applicant]
Cancer Genome Atlas Research. (2013). “Comprehensive Molecular Characterization of Clear Cell Renal Cell Carcinoma,” Nature 499:43-49, 19 pages.
[cited by applicant]
Carter, D.C. et al. (1994). “Structure of Serum Albumin,” Adv. Protein. Chem. 45:153-203.
[cited by applicant]
Citraro, R. et al. (2016, e-pub. Apr. 2, 2016). “mTOR Pathway Inhibition as a New Therapeutic Strategy in Epilepsy and Epileptogenesis,” Pharmacological Research 107:333 to 343.
[cited by applicant]
Curatolo, P. et al. (2016, e-pub. Feb. 29, 2016). “The Role of mTOR Inhibitors in the Treatment of Patients with Tuberous Sclerosis Complex: Evidence-Based and Expert Opinions,” Drugs 76:551-565.
[cited by applicant]
Curry, S. et al. (Sep. 1998). “Crystal Structure of Human Serum Albumin Complexed With Fatty Acid Reveals an Asymmetric Distribution of Binding Sites,” Nat. Struct. Biol. 5(9):827-835.
[cited by applicant]
Dickson, M.A. et al. (Apr. 1, 2013). “Extrarenal Perivascular Epithelioid Cell Tumors (PEComas) Respond to mTOR Inhibition: Clinical and Molecular Correlates,” International Journal of Cancer 132(7):1711-1717.
[cited by applicant]
English language translation of WO 2009/112022 A2. (Year: 2009).
[cited by applicant]
European Search Report mailed on Jan. 20, 2022, for European Patent Application No. 19770483.6, filed on Oct. 15, 2020, 7 pages.
[cited by applicant]
Fang, Y. et al. (Nov. 30, 2001). “Phosphatidic Acid-Mediated Mitogenic Activation of mTOR Signaling,” Science 294(5548):1942-1945.
[cited by applicant]
Fehske, K.J. et al. (1981). “The Location of Drug Binding Sites in Human Serum Albumin,” Biochem. Pharmcol. 30 (7):687-692.
[cited by applicant]
Ferrara, N. (1999). “Molecular and Biological Properties of Vascular Endothelial Growth Factor,” J. Mol. Med. 77:527-543.
[cited by applicant]
Ferrara, N. et al. (Feb. 1997). “The Biology of Vascular Endothelial Growth Factor,” Endocrine Rev. 18(1):4-25.
[cited by applicant]
Finlayson, J.S. (1980). “Albumin Products,” Seminars in Thrombosis and Hemostasis 6(2):85-120.
[cited by applicant]
Garrido, M.J. et al. (Nov.-Dec. 1994). “Characterization of Propofol Binding to Plasma Proteins and Possible Interaction,” Rev. Esp. Anestestiol. Reanim. 41(6):308-312. (English Translation of Abstract Only.).
[cited by applicant]
Gonzalez-Angulo, A.M. et al. (Oct. 1, 2013). “Weekly nab-Rapamycin in Patients With Advanced Nonhematologic Malignancies: Final Results of a Phase I Trial,” Clinical Cancer Research 19(19):5474-5484, 21 pages.
[cited by applicant]
Goodman, L.S. et al. (1996). Goodman & Gilman's The Pharmacological Basis of Therapeutics, 9th Edition, New York, McGraw-Hill, Health Professions Divisions, pp. v-xii, (Table of Contents Only.).
[cited by applicant]
Grabiner, B.C. et al. (May 2014). “A Diverse Array of Cancer-Associated mTOR Mutation are Hyperactivating and Can Predict Rapamycin Sensitivity,” Cancer Discovery 4:554-563.
[cited by applicant]
Green, G.D.J. et al. (Feb. 25, 1981). “Peptidyl Diazomethyl Ketones Are Specific Inactivators of Thiol Proteinases,” J. Biol. Chem. 256(4):1923-1928.
[cited by applicant]
Hanif, F. et al. (2017). “Glioblastoma Multiforme: A Review of its Epidemiology and Pathogenesis through Clinical Presentation and Treatment,” Asian Pacific Journal of Cancer Prevention 18(1):3-9.
[cited by applicant]
Hansel, D.E. et al. (Jun. 2010). “Mammalian Target of Rapamycin (mTOR) Regulates Cellular Proliferation and Tumor Growth in Urothelial Carcinoma,” The American Journal of Pathology 176(6):3062-3072.
[cited by applicant]
Hauser, C.J. et al. (Jun. 1980). “Oxygen Transport Responses to Colloids and Cystalloids in Critically Ill Surgical Patients,” Surgery, Gynecology and Obstetrics 150(6):811-816.
[cited by applicant]
He, X.M. et al. (Jul. 16, 1992). “Atomic Structure and Chemistry of Human Serum Albumin,” Nature 358:209-215.
[cited by applicant]
Houck, K.A. et al. (Dec. 1991). “The Vascular Endothelial Growth Factor Family: Identification of a Fourth Molecular Species and Characterizaion of Alternative Splicing of RNA,” Mol. Endocrin. 5(12):1806-1814.
[cited by applicant]
International Preliminary Report on Patentability mailed on Oct. 1, 2020, for PCT Patent Application No. PCT/US2019/023037, filed on Mar. 19, 2019, 11 pages.
[cited by applicant]
International Search Report and Written Opinion mailed on May 22, 2019, for P*CT Patent Application No. PCT/US2019/023037, filed on Mar. 19, 2019, 15 pages.
[cited by applicant]
Iyer, G. et al. (Oct. 12, 2012). “Genome Sequencing Identifies a Basis for Everolimus Sensitivity,” Science 338 (6104):221.
[cited by applicant]
Jacinto, E. et al. (Nov. 2004, e-pub. Oct. 3, 2004). “Mammalian TOR Complex 2 Controls the Actin Cytoskeleton and is Rapamycin Insensitive,” Nat. Cell Biol. 6(11):1122-1128, Supplementary Information pp. 1-3, total 10 p…
[cited by applicant]
Joazeiro, C. et al. (Aug. 15, 2006). “Proteasome Inhibitor Drugs on the Rise,” Cancer Res. 66(16):7840-7842.
[cited by applicant]
Kabat, J. et al. (2012). “Focal Cortical Dysplasia—Review,” Pol. J. Radiol. 77(2):35-43.
[cited by applicant]
Kerbel, R.S. (Mar. 2000). “Tumor Angiogenesis: Past, Present, and the Near Future,” Carcinogenesis 21 (3):505-515.
[cited by applicant]
Kim, D-H. et al. (Jul. 26, 2002). “mTOR Interacts with Raptor to Form a Nutrient-Sensitive Complex that Signals to the Cell Growth Machinery,” Cell 110:163-175.
[cited by applicant]
Kim, J.C. et al. (2001). “The Limits of Bacillus Calmette-Guerin for Carcinoma in Situ of the Bladder,” The Journal of Urology 165(3):745-756.
[cited by applicant]
Kisselev, A.L. et al. (2001, e-pub. Jul. 12, 2001). “Proteasome Inhibitors: From Research Tools to Drug Candidates,” Chem. Biol. 8(8):739-758.
[cited by applicant]
Knight, Z.A. et al. (May 19, 2006). “A Pharmacological Map of the PI3-K Family Defines a Role for p110a in Insulin Signaling,” Cell 125:733-747.
[cited by applicant]
Kragh-Hansen, U. (Feb. 1990). “Structure and Ligand Binding Properties of Human Serum Albumin,” Dan. Med. Bull. 37(1):57-84.
[cited by applicant]
Krymskaya, V.P. et al. (2011). “mTOR is Required for Pulmonary Arterial Vascular Smooth Muscle Cell Proliferation Under Chronic Hypoxia,” The FASEB Journal 25(6):1922-1933.
[cited by applicant]
Legendre, C. et al. (2003). “Cardiovascular Risk Factors of Sirolimus Compared With Cyclosporine: Early Experience From Two Randomized Trials in Renal Transplantation,” Transplantation proceedings 35(3 Suppl):151S-153S.
[cited by applicant]
Leung, D.W. et al. (Dec. 8, 1989). “Vascular Endothelial Growth Factor is a Secreted Angiogenic Mitogen,” Science 246:1306-1309.
[cited by applicant]
Lim, S.M. et al. (May 20, 2015). “Next-Generation Sequencing to Reveal Somatic Mutations That Confer Sensitivity to Everolimus,” J Clin. Onocl. 33(15): Abstract No. 11010, 3 pages.
[cited by applicant]
Lin, F. et al. (2013). “Dual mTORC1 and mTORC2 Inhibitor Palomid 529 Penetrates the Blood-brain Barrier Without Restriction by ABCB1 and ABCG2,” In J. Cancer 133(5):1222-1234.
[cited by applicant]
Lyden, D. et al. (2001). “Impaired Recruitment of Bone-Marrow-Derived Endothelial and Hematopoietic Precursor Cells Blocks Tumor Angiogenesis and Growth.” Nat. Med. 7:1194-1201.
[cited by applicant]
Maglietta, R. et al. (2007, e-pub. May 31, 2007). “Statistical Assessment of Functional Categories of Genes Deregulated in Pathological Conditions by Using Microarray Data,” Bioinformatics 23:2063-2072.
[cited by applicant]
Manton, C.A. et al. (Jan. 25, 2016). “Induction of Cell Death by the Novel Proteasome Inhibitor Marizomib in Glioblastoma in Vitro and in Vivo,” Scientific Reports, 6(18953):1-16.
[cited by applicant]
McKiernan, J.M. et al. (2010). “Phase II Trial of Intracesical Nanoparticle Albumin-Bound (nab-) Paclitaxel for the Treatment of Non-Muscle Invasive Urothelial Carcinoma of the Bladder after BCG Treatment Failure,” The …
[cited by applicant]
Muller, B.G. et al. (1996). “Albumin Nanospheres as Carriers for Passive Drug Targeting: An Optimized Manufacturing Technique,” Pharmaceutical Research 13(1):32-37.
[cited by applicant]
Novak, B.A. et al. (2006, e-pub. Nov. 8, 2005). Pathway Recognition and Augmentation by Computational Analysis of Microarray Expression Data, Bioinformatics 22(2):233-241.
[cited by applicant]
Parkes, C. et al. (Sep. 1, 1985). “Calpain Inhibition by Peptide Epoxides,” Biochem. J. 230:509-516.
[cited by applicant]
Paal, K. et al. (2001). “High Affinity Binding of Paclitaxel to Human Serum Albumin,” Eur. J. Biochem. 268 (7):2187-2191.
[cited by applicant]
Presta, L.G. et al. (Oct. 15, 1997). “Humanization of an Anti-Vascular Endothelial Growth Factor Monoclonal Antibody for the Therapy of Solid Tumors and Other Disorders,” Cancer Res. 57:4593-4599.
[cited by applicant]
Purcell, M. et al. (2000). “Interaction of Taxol With Human Serum Albumin,” Biochim. Biophys. Acta. 1478:61-68.
[cited by applicant]
Roper, J. et al. (Sep. 26, 2011). “The Dual PI3K/mTOR Inhibitor NVP-BEZ235 Induces Tumor Regression in a Genetically Engineered Mouse Model of PIK3CA Wild-Type Colorectal Cancer,” PLoS One 6(9):e25132, 10 pages.
[cited by applicant]
Sarbassov, D.D. et al. (Jul. 27, 2004). “Rictor, a Novel Binding Partner of mTOR, Defines a Rapamycin-Insensitive and Raptor Independent Pathway that Regulates the Cytoskeleton,” Curr. Biol. 14:1296-1302.
[cited by applicant]
Seager, C.M. et al. (Dec. 1, 2009). “Intravesical Delivery of Rapamycin Suppresses Tumorigenesis in a Mouse Model of Progressive Bladder Cancer,” Cancer Prevention Research 2(12):1008-1014.
[cited by applicant]
Segal, E. et al. (Jun. 2003). “Module Networks: Identifying Regulatory Modules and Their Condition-Specific Regulators From Gene Expression Data,” Nat. Genet. 34(2):166-176.
[cited by applicant]
Segal, E. et al. (Oct. 2004, e-pub. Sep. 26, 2004) “A Module Map Showing Conditional Activity of Expression Modules in Cancer,” Nat. Genet. 36(10):1090-1098.
[cited by applicant]
Sirven, J.I. (Sep. 2015). “Epilepsy: A Spectrum Disorder,” Cold Spring Harbor Prespect. Med. 5(9):1-16.
[cited by applicant]
Sugio, S. et al. (1999). “Crystal Structure of Human Serum Albumin at 2.5 Å Resolution,” Protein. Eng. 12(6):439-446.
[cited by applicant]
Tian, L. et al. (Sep. 20, 2005). “Discovering Statistically Significant Pathways in Expression Profiling Studies,” Proc Nat'l Acad Sci USA 102:13544-13549.
[cited by applicant]
Tullis, J.L. (Jan. 24, 1977). “Albumin. 1. Background and Use,” JAMA 237(4): 355-360.
[cited by applicant]
Tullis, J.L. (Jan. 31, 1977). “Albumin. 2. Guidelines for Clinical Use,” JAMA 237(5):460-463.
[cited by applicant]
Urien, S. et al. (May 1996). “Docetaxel Serum Protein Binding With High Affinity to Alpha-Acid Glycoprotein,” Invest. New Drugs 147:147-151.
[cited by applicant]
Verhaak, R.G.W. et al. (Jan. 19, 2010). “Integrated Genomic Analysis Identifies Clinically Relevant Subtypes of Glioblastoma Characterized by Abnormalities in PDGFRA, IDH1, EGFR, and NF1,” Cancer Cell 17(1):98-110.
[cited by applicant]
Vlasak, R. et al. (May 1989). “Influenza C Virus Esterase: Analysis of Catalytic Site, Inhibition, and Possible Function,” J. VIrol. 63(5):2056-2062.
[cited by applicant]
Vörum, H. (Nov. 1999). “Reversible Ligand Binding to Human Serum Albumin,” Dan. Med. Bull. 46(5):379-399.
[cited by applicant]
Wagle, N. et al. (2012). “High-Throughout Detection of Actionable Genomic Alterations in Clinical Tumor Samples by Targeted, Massively Parallel Sequencing,” Cancer discovery 2.1:82-93.
[cited by applicant]
Wagle, N. et al. (2014). “Response and Acquired Resistance to Everolimus in Anaplastic Thyroid Cancer,” N. Eng. J. Med. 371:1426-1433.
[cited by applicant]
Wagle, N. et al. (May 2014). “Activating mTOR Mutationsin a Patient with an Extraordinary Response on a Phase I Trial of Everolimus and Pazopanib,” Cancer Discovery 4:546-553.
[cited by applicant]
Weathers, S-P. et al. (Sep. 2016). “A Randomized Phase II Trial of Standard Dose Bevacizumab Versus Low Dose Bevacizumab Plus Lomustine (CCNU) in Adults With Recurrent Glioblastoma,” J. Neurooncol. 129(3):487-494, 16 pa…
[cited by applicant]
European Examination mailed on Jul. 30, 2024, for European Patent Application No. 19770483.6, filed on Oct. 15, 1 2020, 5 pages.
[cited by applicant]